Omazic B, Hentschke P, Näsman-Björk I, Mattsson J, Oxelius V-A, Ringdén O, Barkholt L, Permert J, Lundkvist I
Arvid Wretlind Laboratory at the Center for Surgical Sciences, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm,Sweden.
Scand J Immunol. 2005 Jan;61(1):72-81. doi: 10.1111/j.0300-9475.2005.01528.x.
The objective of this study was to investigate B-lymphocyte reconstitution in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) after myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. B-lymphocyte reconstitution was studied by monitoring the CDR3 repertoire with spectratyping. We demonstrate a delay in the recovery of the B-lymphocyte repertoire, measured by variation in size distribution of the immunoglobulin H CDR3 in patients conditioned with RIC compared to MAC. We found no general explanation for this finding, but when clinical data for each patient were studied in detail, we could identify a cause for the oligoclonality of the B-lymphocyte repertoire after HSCT with RIC for each of the patients. Older patients and donors, low cell dose at transplantation, relapse, graft-versus-host disease (GVHD) and its treatment as well as cytomegalovirus infection and its treatment are all possible causes for the restriction of the B-lymphocyte repertoire observed in this study. Taken together, reconstitution of the B-lymphocyte repertoire after HSCT is a process dependent on multiple factors and differs between patients. The conditioning regimen may be of importance, but data from this study suggest that individual factors and the various complications occurring after HSCT are more likely to determine the development of the B-lymphocyte repertoire.
本研究的目的是调查接受清髓性预处理(MAC)或减低剂量预处理(RIC)方案的异基因造血干细胞移植(HSCT)患者的B淋巴细胞重建情况。通过用光谱分型监测互补决定区3(CDR3)库来研究B淋巴细胞重建。我们证明,与接受MAC预处理的患者相比,接受RIC预处理的患者中,通过免疫球蛋白H CDR3大小分布变化来衡量的B淋巴细胞库恢复存在延迟。我们没有找到对此发现的普遍解释,但在详细研究每位患者的临床数据时,我们能够为接受RIC预处理的HSCT后每位患者B淋巴细胞库寡克隆性确定一个原因。老年患者和供者、移植时细胞剂量低、复发、移植物抗宿主病(GVHD)及其治疗以及巨细胞病毒感染及其治疗都是本研究中观察到的B淋巴细胞库受限的可能原因。综上所述,HSCT后B淋巴细胞库的重建是一个依赖多种因素的过程,且患者之间存在差异。预处理方案可能很重要,但本研究数据表明,个体因素以及HSCT后发生的各种并发症更有可能决定B淋巴细胞库的发展。